Akeso Announced Collaboration with Chipscreen Biosciences to Initiated a Clinical Trial of PD-1/CTLA-4 Bi-specific Antibody in Combination with Chiauranib for PD-(L)1 Pretreated ES-SCLC

-Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer.